Entrogyl-OZ Tablet is a combination pharmaceutical formulation containing Diloxanide 375 mg, Ornidazole 250 mg, and Simethicone 25 mg, designed for the effective management of amoebic infections and associated gastrointestinal disturbances. Diloxanide acts as a luminal amoebicide, targeting and eradicating Entamoeba histolytica cysts within the intestinal lumen, thereby preventing relapse and transmission. Ornidazole, a nitroimidazole derivative, exhibits potent antiprotozoal and antibacterial activity by disrupting DNA synthesis in anaerobic pathogens, effectively treating invasive amoebiasis and mixed anaerobic infections. Simethicone, an anti-foaming agent, facilitates the relief of bloating and discomfort by reducing gas accumulation in the gastrointestinal tract. Entrogyl-OZ is indicated for the treatment of amoebic dysentery, amoebic liver abscess, and other protozoal infections accompanied by excessive intestinal gas and flatulence. The combination therapy ensures comprehensive eradication of both luminal and tissue forms of the parasite while alleviating gastrointestinal symptoms. It is recommended to be administered under medical supervision, with dosage adjustments based on the severity of infection and patient response. Caution is advised in patients with hypersensitivity to nitroimidazoles or simethicone and those with hepatic or renal impairment. This formulation offers a synergistic approach to managing complex amoebic infections and improving patient comfort.